Targets › DMD
16 programs from 13 companies in 22 trials: 9 Phase 1, 6 Phase 3, 5 Phase 2, 2 Phase 4; Neurology, Psychiatry, Hematology; next expected readout Nov 2026.
Anchors the extracellular matrix to the cytoskeleton via F-actin. Ligand for dystroglycan. (UniProt, P11532)
Open in Phaseline: the race on DMD, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Sarepta Therapeutics | delandistrogene moxeparvovec Dystrophin exogenous gene | DMD | Phase 4 | Duchenne Muscular Dystrophy | May 2027 |
| NS Pharma | Viltolarsen Dystrophin pre-mRNA positive modulator | DMD | Phase 4 | Duchenne Muscular Dystrophy | Sep 2032 |
| Avidity Biosciences | AOC 1044 antisense oligonucleotide for exon 44 skipping | DMD | Phase 3 | Muscular Dystrophies; DMD | Apr 2027 |
| Solid Biosciences | SGT-003 Adeno-associated virus serotype SLB101 gene therapy delivering human microdystrophin gene | DMD | Phase 3 | Duchenne Muscular Dystrophy | May 2027 |
| Dyne Therapeutics | Zeleciment Rostudirsen (DYNE-251) Antisense oligonucleotide for exon 51 skipping | DMD | Phase 3 | Duchenne Muscular Dystrophy (DMD) | Dec 2030 |
| Sarepta Therapeutics | Eteplirsen Dystrophin pre-mRNA positive modulator | DMD | Phase 3 | Muscular Dystrophy, Duchenne | – |
| NS Pharma | NS-089/NCNP-02 Exon 44 skipping agent | DMD | Phase 2 | Duchenne Muscular Dystrophy | Feb 2027 |
| Nippon Shinyaku | NS-089/NCNP-02 (Brogidirsen) Antisense oligonucleotide targeting DMD exon 45 skip | DMD | Phase 2 | Duchenne Muscular Dystrophy (DMD) | Apr 2027 |
| REGENXBIO | RGX-202 Recombinant AAV8 gene therapy delivering novel microdystrophin transgene with C-terminal d | DMD | Phase 2 | Duchenne Muscular Dystrophy | Jun 2028 |
| Genethon | GNT0004 AAV8-delivered sequence-optimized microdystrophin gene therapy | DMD | Phase 2 | Duchene Muscular Dystrophy | Oct 2028 |
| Solid Biosciences | SGT-001 AAV9 vector-mediated microdystrophin gene transfer | DMD | Phase 1 | Duchenne Muscular Dystrophy | Nov 2026 |
| Wave Life Sciences USA | WVE-N531 Antisense oligonucleotide (ASO) targeting exon 53 skipping in DMD | DMD | Phase 1 | Duchenne Muscular Dystrophy | Apr 2027 |
| Belief BioMed (Beijing) | BBM-D101 AAV-mediated gene addition therapy delivering dystrophin-associated protein complex therap | DMD | Phase 1 | DMD | Jun 2027 |
| Insmed Gene Therapy | INS1201 Gene therapy for Duchenne muscular dystrophy | DMD | Phase 1 | Duchenne Muscular Dystrophy | Jan 2028 |
| AO GENERIUM | GNR-097 AAV9-delivered truncated dystrophin gene therapy (micro-dystrophin) | DMD | Phase 1 | Duchenne Muscular Dystrophy | Aug 2029 |
| Precision BioSciences | PBGENE-DMD Ex vivo gene editing therapy targeting DMD mutations amenable to exons 45-55 excision | DMD | Phase 1 | Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD | Nov 2029 |
Duchenne Muscular Dystrophy (13) Duchenne Muscular Dystrophy (DMD) (3) DMD (2) Duchene Muscular Dystrophy (1) Muscular Dystrophies (1) Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD (1) Muscular Dystrophy, Duchenne (1)
other (13), small molecule (2), protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.